124 related articles for article (PubMed ID: 7883753)
1. Activation of the alternative pathway of human complement by apoptotic human umbilical vein endothelial cells.
Tsuji S; Kaji K; Nagasawa S
J Biochem; 1994 Oct; 116(4):794-800. PubMed ID: 7883753
[TBL] [Abstract][Full Text] [Related]
2. Deposition of C3b and iC3b onto particulate activators of the human complement system. Quantitation with monoclonal antibodies to human C3.
Newman SL; Mikus LK
J Exp Med; 1985 Jun; 161(6):1414-31. PubMed ID: 2409200
[TBL] [Abstract][Full Text] [Related]
3. Formation of covalently linked C3-C3 dimers on IgG immune aggregates.
Barrio E; Antón LC; Marqués G; Sánchez A; Vivanco F
Eur J Immunol; 1991 Feb; 21(2):343-9. PubMed ID: 1999223
[TBL] [Abstract][Full Text] [Related]
4. The requirement of localized, CR2-mediated, alternative pathway activation of complement for covalent deposition of C3 fragments on normal B cells.
Olesen EH; Johnson AA; Damgaard G; Leslie RG
Immunology; 1998 Feb; 93(2):177-83. PubMed ID: 9616366
[TBL] [Abstract][Full Text] [Related]
5. C3b2-IgG complexes retain dimeric C3 fragments at all levels of inactivation.
Jelezarova E; Luginbuehl A; Lutz HU
J Biol Chem; 2003 Dec; 278(51):51806-12. PubMed ID: 14527961
[TBL] [Abstract][Full Text] [Related]
6. Activation, binding, and processing of complement component 3 (C3) by Blastomyces dermatitidis.
Zhang MX; Klein B
Infect Immun; 1997 May; 65(5):1849-55. PubMed ID: 9125571
[TBL] [Abstract][Full Text] [Related]
7. The binding of complement component C3 to antibody-antigen aggregates after activation of the alternative pathway in human serum.
Gadd KJ; Reid KB
Biochem J; 1981 May; 195(2):471-80. PubMed ID: 7316962
[TBL] [Abstract][Full Text] [Related]
8. Reoxygenation of hypoxic human umbilical vein endothelial cells activates the classic complement pathway.
Collard CD; Väkevä A; Büküsoglu C; Zünd G; Sperati CJ; Colgan SP; Stahl GL
Circulation; 1997 Jul; 96(1):326-33. PubMed ID: 9236453
[TBL] [Abstract][Full Text] [Related]
9. Complement activation by apoptotic endothelial cells following hypoxia/reoxygenation.
Mold C; Morris CA
Immunology; 2001 Mar; 102(3):359-64. PubMed ID: 11298836
[TBL] [Abstract][Full Text] [Related]
10. Activation of the alternative pathway of complement by apoptotic Jurkat cells.
Matsui H; Tsuji S; Nishimura H; Nagasawa S
FEBS Lett; 1994 Sep; 351(3):419-22. PubMed ID: 7521852
[TBL] [Abstract][Full Text] [Related]
11. Development and application of an enzyme-linked immunosorbent assay for the quantitation of alternative complement pathway activation in human serum.
Mayes JT; Schreiber RD; Cooper NR
J Clin Invest; 1984 Jan; 73(1):160-70. PubMed ID: 6418767
[TBL] [Abstract][Full Text] [Related]
12. Biosynthesis of complement factor H by human umbilical vein endothelial cells. Regulation by T cell growth factor and IFN-gamma.
Brooimans RA; Hiemstra PS; van der Ark AA; Sim RB; van Es LA; Daha MR
J Immunol; 1989 Mar; 142(6):2024-30. PubMed ID: 2522130
[TBL] [Abstract][Full Text] [Related]
13. Complement activation occurs on subendothelial extracellular matrix in vitro and is initiated by retraction or removal of overlying endothelial cells.
Hindmarsh EJ; Marks RM
J Immunol; 1998 Jun; 160(12):6128-36. PubMed ID: 9637530
[TBL] [Abstract][Full Text] [Related]
14. Interaction of C3 with antigen-antibody complexes in the process of solubilization of immune precipitates.
Takata Y; Tamura N; Fujita T
J Immunol; 1984 May; 132(5):2531-7. PubMed ID: 6232320
[TBL] [Abstract][Full Text] [Related]
15. C5 convertase of the alternative complement pathway: covalent linkage between two C3b molecules within the trimolecular complex enzyme.
Kinoshita T; Takata Y; Kozono H; Takeda J; Hong KS; Inoue K
J Immunol; 1988 Dec; 141(11):3895-901. PubMed ID: 3183384
[TBL] [Abstract][Full Text] [Related]
16. In vitro biosynthesis of complement factor I by human endothelial cells.
Julen N; Dauchel H; Lemercier C; Sim RB; Fontaine M; Ripoche J
Eur J Immunol; 1992 Jan; 22(1):213-7. PubMed ID: 1530917
[TBL] [Abstract][Full Text] [Related]
17. The third component of complement: covalent attachment of a radioactive sugar to the labile binding site of C3 via the alternative pathway.
Mann J; O'Brien R; Hostetter MK; Alper CA; Rosen FS; Babior BM
J Immunol; 1981 Jun; 126(6):2370-2. PubMed ID: 6785350
[TBL] [Abstract][Full Text] [Related]
18. C3 binds with similar efficiency to Fab and Fc regions of IgG immune aggregates.
Antón LC; Ruiz S; Barrio E; Marqués G; Sánchez A; Vivanco F
Eur J Immunol; 1994 Mar; 24(3):599-604. PubMed ID: 8125130
[TBL] [Abstract][Full Text] [Related]
19. Bovine conglutinin binds to an oligosaccharide determinant presented by iC3b, but not by C3, C3b or C3c.
Laursen SB; Thiel S; Teisner B; Holmskov U; Wang Y; Sim RB; Jensenius JC
Immunology; 1994 Apr; 81(4):648-54. PubMed ID: 7518801
[TBL] [Abstract][Full Text] [Related]
20. Covalent linkage of C3 to properdin during complement activation.
Whiteman LY; Purkall DB; Ruddy S
Eur J Immunol; 1995 May; 25(5):1481-4. PubMed ID: 7774654
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
